Compare Edgewise Therapeutics Inc. Common Stock (EWTX) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edgewise Therapeutics Inc. Common Stock vs TJX Companies Inc — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.04 (market cap $3.94B), while TJX Companies Inc trades at $143.25 (market cap $155.64B). The key difference: TJX Companies Inc is far larger — about 39.5× Edgewise Therapeutics Inc. Common Stock's market cap, and TJX Companies Inc pays a 1.36% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and TJX Companies Inc for 97 Days on average.
| EWTX | TJX | |
|---|---|---|
Market Cap | $3.94B | $155.64B |
Volume | 810,104 | 7,499,607 |
Sector | Health | Consumer Cyclical |
52-Week High | $48.35 | $168.41 |
52-Week Low | $14.89 | $122.84 |
Typical Hold Time | 0 Days | 97 Days |
Enterprise Value | $3.48B | $163.95B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TJX trades at $142.80, up 0.62% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $56.36B in 2025, with net income of $4.86B and a high ROE of 62.17%. The stock is near its pivot point of $141, with resistance at $143 and support at $139. Analysts are overwhelmingly positive, with an 84.9% buy rating and a consensus price target of $174.15.
Outlook remains positive due to consistent earnings outperformance and projected revenue growth to $62.4B in 2026. Risks include high valuation multiples (P/E 26.2) and competitive pressures in off-price retail. Upside potential is supported by Wall Street optimism and strong cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Edgewise Therapeutics Inc. Common Stock
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
